Wire · opportunities
BMS welcomes new multiple myeloma drug as generics batter current portfolio
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 August 2026 · Fusion42 review
The FDA granted accelerated approval to Bristol Myers Squibb's new multiple myeloma drug Zenbexus (iberdomide), enabling BMS to combat steep sales declines of its existing myeloma drugs caused by generic competition. Zenbexus is priced higher than expected and aims for over $1 billion in annual sales by 2031, backed by strong Phase 3 data.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.
◆ ◆ The Wire takeaway
Your oncology drug business just faced a major revenue squeeze from generics but now BMS has FDA approval to push a premium novel drug. If you build or sell multiple myeloma treatments, this raises the bar for pricing and clinical evidence to reclaim lost market share.
◆ Coverage
12 sources · first reported 13 Aug 2026 · latest 17 Aug 2026
◆ Topics